The Race to Market: Five Potential Blockbuster GLP-1 Therapies in 2024

In the fast-paced world of pharmaceutical development, the race to bring new and innovative therapies to market is always a thrilling competition. In 2024, there are five potential blockbuster GLP-1 therapies vying for approval and eager to make their mark in the field of medical advancements. Let's take a closer look at these promising candidates and their unique features that could shape the future of GLP-1 treatment.

1. Danuglipron: Convenience and Safety in a Once-Daily Oral Dose

Danuglipron, developed by Pfizer, stands out due to its once-daily oral administration, offering a convenient alternative to the weekly subcutaneous injections of Wegovy and Zepbound. Pfizer believes that a small molecule oral GLP-1 receptor agonist, like Danuglipron, can improve safety and tolerability compared to peptide-based counterparts. Pfizer's ongoing Phase I clinical trial, with once-daily dosing, is set to conclude in May, and if the safety results are positive, the drug may directly advance to Phase III trials.

2. ECC5004: Targeting Cardiovascular and Renal Benefits

ECC5004, acquired by AstraZeneca through a licensing agreement with Chia Tai Tianqing Pharmaceutical Group, is a low-dose, once-daily small molecule GLP-1 receptor agonist. Early-stage trials for ECC5004 have shown promising results in terms of weight loss and improved glucose control in patients with type 2 diabetes. AstraZeneca plans to initiate Phase II studies later this year, targeting overweight patients and those with type 2 diabetes, with the potential for combination therapy involving AstraZeneca's existing drugs for chronic kidney disease and heart failure.

3. Retatrutide: Unleashing Greater Weight Loss Potential

Retatrutide, developed by Novo Nordisk, is a GLP-1 receptor agonist that also acts on a third hormone receptor, pancreatic polypeptide. Phase II clinical trial results have demonstrated impressive weight loss of 24% in obese patients after approximately one year of treatment, surpassing the results of Wegovy and Zepbound. Novo Nordisk is conducting Phase III trials in obese patients with knee osteoarthritis and both with and without diabetes, with data expected to be released in 2025. Additionally, Phase II trials are exploring the potential of retatrutide to improve kidney function in overweight and obese patients with chronic kidney disease.

4. Survodutide: Targeting NASH and Liver Fibrosis

Survodutide, a dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist, is being investigated for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis. Preclinical and Phase II studies have shown promising results, indicating the potential of survodutide in addressing these conditions. Zealand Pharma and Boehringer Ingelheim are collaborating on the development of survodutide, and data from ongoing trials are expected to be released in the first half of 2024.

5. MariTide: Prolonged Weight Loss Effects

MariTide, developed by Amgen, is a promising GLP-1 therapy that has shown significant potential for sustained weight loss. While specific details about MariTide are limited in the provided information, Amgen claims that it offers a solution to address the most pressing concerns associated with GLP-1 therapies.

The year 2024 holds immense promise for the field of GLP-1 therapy, with five potential blockbuster candidates striving to make their mark. Each therapy brings its own unique advantages, such as convenience, cardiovascular benefits, enhanced weight loss potential, and potential applications in treating liver diseases. As these therapies progress through clinical trials and regulatory processes, the medical community eagerly awaits their arrival, anticipating the positive impact they may have on patients' lives. The race to market is on, and only time will reveal which therapy will emerge as the first to "go ashore" and revolutionize GLP-1 treatment.